BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 30446941)

  • 21. Minimal residual disease in acute myelogenous leukemia.
    Cruz NM; Mencia-Trinchant N; Hassane DC; Guzman ML
    Int J Lab Hematol; 2017 May; 39 Suppl 1(Suppl 1):53-60. PubMed ID: 28447422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Test Then Erase? Current Status and Future Opportunities for Measurable Residual Disease Testing in Acute Myeloid Leukemia.
    Blackmon AL; Hourigan CS
    Acta Haematol; 2024; 147(2):133-146. PubMed ID: 38035547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
    Dominietto A
    Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of minimal residual disease in acute myeloid leukemia.
    Kern W; Schoch C; Haferlach T; Schnittger S
    Crit Rev Oncol Hematol; 2005 Nov; 56(2):283-309. PubMed ID: 16213150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.
    Freeman SD; Virgo P; Couzens S; Grimwade D; Russell N; Hills RK; Burnett AK
    J Clin Oncol; 2013 Nov; 31(32):4123-31. PubMed ID: 24062403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection and management of acute myeloid leukemia measurable residual disease: is it standard of care?
    Paterno G; Del Principe MI; Venditti A
    Curr Opin Hematol; 2020 Mar; 27(2):81-87. PubMed ID: 31895104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC-MRD and treatment guidance for elderly patients.
    Sun Y; Zhu G; Zhong H
    Eur J Haematol; 2024 Jun; 112(6):870-878. PubMed ID: 38342613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia.
    Lacombe F; Campos L; Allou K; Arnoulet C; Delabarthe A; Dumezy F; Feuillard J; Geneviève F; Guérin E; Guy J; Jouault H; Lepelley P; Maynadié M; Solly F; Ballon OW; Preudhomme C; Baruchel A; Dombret H; Ifrah N; Béné MC;
    Hematol Oncol; 2018 Apr; 36(2):422-428. PubMed ID: 29218734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of multiparameter flow cytometry for disease monitoring in AML.
    Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
    Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A; Gillis D; Lewis I
    Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
    Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
    Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Measurable Residual Disease (MRD) in Hematopoietic Stem Cell Transplantation for Hematological Malignancies Focusing on Acute Leukemia.
    Czyz A; Nagler A
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of minimal residual disease in acute myeloid leukemia.
    Grimwade D; Vyas P; Freeman S
    Curr Opin Oncol; 2010 Nov; 22(6):656-63. PubMed ID: 20805746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is it time to routinely incorporate MRD into practice?
    Ravandi F
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):396-400. PubMed ID: 30466755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT.
    Nagler A; Baron F; Labopin M; Polge E; Esteve J; Bazarbachi A; Brissot E; Bug G; Ciceri F; Giebel S; Gilleece MH; Gorin NC; Lanza F; Peric Z; Ruggeri A; Sanz J; Savani BN; Schmid C; Shouval R; Spyridonidis A; Versluis J; Mohty M
    Bone Marrow Transplant; 2021 Jan; 56(1):218-224. PubMed ID: 32724200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease.
    Momen N; Tario J; Fu K; Qian YW
    J Hematop; 2023 Jun; 16(2):85-94. PubMed ID: 38175444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
    Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.
    Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf Å; Deneberg S; Jädersten M; Antunovic P; Cammenga J; Möllgård L; Wennström L; Ölander E; Ehinger M; Fogelstrand L; Höglund M; Lazarevic VL
    Leuk Lymphoma; 2021 Aug; 62(8):1973-1981. PubMed ID: 33719843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.